Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/21069
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ong, Doen Ming | - |
dc.contributor.author | Ashby, Michael | - |
dc.contributor.author | Grigg, Andrew P | - |
dc.contributor.author | Gard, Grace | - |
dc.contributor.author | Ng, Zi Y | - |
dc.contributor.author | Huang, Huayi Ellen | - |
dc.contributor.author | Chong, Yee Shuen | - |
dc.contributor.author | Cheah, Chan Yoon | - |
dc.contributor.author | Devitt, Bianca | - |
dc.contributor.author | Chong, Geoffrey | - |
dc.contributor.author | Loh, Zoe | - |
dc.contributor.author | Mo, Allison | - |
dc.contributor.author | Hawkes, Eliza A | - |
dc.date | 2019-06-17 | - |
dc.date.accessioned | 2019-06-24T02:06:08Z | - |
dc.date.available | 2019-06-24T02:06:08Z | - |
dc.date.issued | 2019-10 | - |
dc.identifier.citation | British journal of haematology 2019; 187(1): 73-81 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/21069 | - |
dc.description.abstract | Elderly patients may be heterogeneous in their abilities to tolerate immunochemotherapy-associated toxicities. We describe the morbidity of rituximab-chemotherapy combinations among 205 newly-diagnosed diffuse large B-cell lymphoma (DLBCL) patients aged ≥60 years from 3 tertiary hospitals between 2009 and 2016, and explore the utility of retrospectively-assigned baseline Comprehensive Geriatric Assessment (CGA) in predicting these toxicities. Seventy-three percent (146/201) experienced grade ≥3 toxicities, 81% (163/201) needed admission, 52% (107/205) had ≥2 unplanned admissions, 82/201 (41%) required dose reductions (DR) subsequent to Cycle 1, 39/166 (23%) had chemotherapy delays and 26/198 (13%) ceased therapy early. CGA was associated with pre-emptive baseline DR and perhaps because of this, did not predict grade ≥3 toxicities, ≥2 unplanned admissions or subsequent DR. Three-year overall survival (OS) of CGA-fit, CGA-unfit and CGA-frail patients was 82%, 60% and 53%, respectively. Three-year progression-free survival (PFS) of CGA-fit, CGA-unfit and CGA-frail patients was 66%, 58% and 46%, respectively. OS of CGA-fit patients was not statistically different from CGA-unfit patients, but was superior to CGA-frail patients (hazard ratio 2·892, 95% confidence interval 1·275-6·559, P = 0·011). PFS differences were not statistically significant. Baseline DR and early therapy cessation were associated with inferior OS and PFS independent of CGA. Prospective studies are needed to confirm if CGA-adapted treatment strategies minimize morbidity and improves survival. | - |
dc.language.iso | eng | - |
dc.subject | DLBCL | - |
dc.subject | Geriatric assessment | - |
dc.subject | elderly | - |
dc.subject | lymphoma | - |
dc.subject | morbidity | - |
dc.title | Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations. | - |
dc.type | Journal Article | - |
dc.identifier.journaltitle | British journal of haematology | - |
dc.identifier.affiliation | Department of Haematology, Austin Health, Heidelberg, Victoria, Australia | - |
dc.identifier.affiliation | Department of Medical Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia | - |
dc.identifier.affiliation | Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia | en |
dc.identifier.affiliation | Medical School, University of Western Australia, Crawley, Australia | en |
dc.identifier.affiliation | Department of Oncology, Eastern Health, Melbourne, Australia | en |
dc.identifier.affiliation | Department of Haematology, Eastern Health, Melbourne, Australia | en |
dc.identifier.affiliation | Department of Haematology, Pathwest Laboratory Medicine, Nedlands, Western Australia, Australia | en |
dc.identifier.affiliation | Eastern Health Clinical School, Monash University, Melbourne, Australia | en |
dc.identifier.doi | 10.1111/bjh.16049 | - |
dc.identifier.orcid | 0000-0003-4097-8583 | - |
dc.identifier.orcid | 0000-0002-9215-1441 | - |
dc.identifier.orcid | 0000-0002-1923-3133 | - |
dc.identifier.orcid | 0000-0002-0376-2559 | - |
dc.identifier.pubmedid | 31206608 | - |
dc.type.austin | Journal Article | - |
local.name.researcher | Chong, Geoffrey | |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
crisitem.author.dept | Clinical Haematology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
crisitem.author.dept | Clinical Haematology | - |
crisitem.author.dept | Pathology | - |
crisitem.author.dept | Clinical Haematology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.